An MIT-spinout drug discovery company applying AI to untargeted metabolomics to find metabolite drivers of cancer and cardio-metabolic disease.
ReviveMed
Released January 27, 2025
Pretrained variational autoencoder for untargeted blood metabolomics, learning metabolite representations that transfer to clinical prediction tasks.